HDM1005
Phase Ib Clinical Study of HDM1005 Injection
Huadong Medicine · Phase 1 · Completed · Enrollment 80
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| HDM1005 injection dose level 1(Part 1) | n/r | n/r | n/r | n/r |
| HDM1005 injection dose level 2 (Part 1) | n/r | n/r | n/r | n/r |
| HDM1005 injection dose level 3 (Part 1) | n/r | n/r | n/r | n/r |
| HDM1005 injection dose level 4 (Part 1) | n/r | n/r | n/r | n/r |
| Experimental: HDM1005 injection one dose level with stepwise titration from a lower dose (Part 2) | n/r | n/r | n/r | n/r |
Not shown
- HDM1005 injection dose level 1(Part 1): endpoint not reported
- HDM1005 injection dose level 2 (Part 1): endpoint not reported
- HDM1005 injection dose level 3 (Part 1): endpoint not reported
- HDM1005 injection dose level 4 (Part 1): endpoint not reported
- Experimental: HDM1005 injection one dose level with stepwise titration from a lower dose (Part 2): endpoint not reported